Stimulation of ß3 adrenergic receptors as a new therapeutic target in pulmonary hypertension. (Q3155217): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): Pulmonary hypertension (PH) includes a number of diseases characterised by increased pulmonary arterial pressure and pulmonary vascular resistance (RVP) and progressive deterioration of right ventricle function. Overall its prevalence is high and is associated with poor prognosis. We currently have few therapeutic alternatives, mainly in PH secondary to left heart disease (the most common one). Stimulation of ß3 adrenergic receptors produces a...) |
(Created claim: summary (P836): Pulmonary hypertension (PH) includes a number of diseases characterised by increased pulmonary arterial pressure and pulmonary vascular resistance (RVP) and progressive deterioration of right ventricle function. Overall its prevalence is high and is associated with poor prognosis. We currently have few therapeutic alternatives, mainly in PH secondary to left heart disease (the most common one). Stimulation of ß3 adrenergic receptors produces art...) |
||||||||||||||
| Property / summary | |||||||||||||||
Pulmonary hypertension (PH) includes a number of diseases characterised by increased pulmonary arterial pressure and pulmonary vascular resistance (RVP) and progressive deterioration of right ventricle function. Overall its prevalence is high and is associated with poor prognosis. We currently have few therapeutic alternatives, mainly in PH secondary to left heart disease (the most common one). Stimulation of ß3 adrenergic receptors produces arterial vasodilation in in vitro studies and reduction of ventricular remodeling in murine models of left ventricular overload. In pilot experiments, we have observed that the administration of ß3 agonists causes a reduction in RVP in chronic HP models in large animal, something never reported. Our hypothesis is that ß3 stimulation is a potential therapy in PH by reducing pulmonary arterial tone and remodeling and impairment of right ventricle function. In order to evaluate the beneficial effect of this new therapy at the pulmonary and cardiac level and to investigate the mechanism(s) of action, we present a translational project that includes in vitro studies on human cell lines and pulmonary arteries and HP models in rodents and pigs. In large animal experimental studies, reference diagnostic procedures shall be used in clinical practice: right cardiac catheterisation and magnetic resonance imaging, which will facilitate the transfer of knowledge to patients. The development of a new therapy for patients with PH would have a great clinical impact. (English) | |||||||||||||||
| Property / summary: Pulmonary hypertension (PH) includes a number of diseases characterised by increased pulmonary arterial pressure and pulmonary vascular resistance (RVP) and progressive deterioration of right ventricle function. Overall its prevalence is high and is associated with poor prognosis. We currently have few therapeutic alternatives, mainly in PH secondary to left heart disease (the most common one). Stimulation of ß3 adrenergic receptors produces arterial vasodilation in in vitro studies and reduction of ventricular remodeling in murine models of left ventricular overload. In pilot experiments, we have observed that the administration of ß3 agonists causes a reduction in RVP in chronic HP models in large animal, something never reported. Our hypothesis is that ß3 stimulation is a potential therapy in PH by reducing pulmonary arterial tone and remodeling and impairment of right ventricle function. In order to evaluate the beneficial effect of this new therapy at the pulmonary and cardiac level and to investigate the mechanism(s) of action, we present a translational project that includes in vitro studies on human cell lines and pulmonary arteries and HP models in rodents and pigs. In large animal experimental studies, reference diagnostic procedures shall be used in clinical practice: right cardiac catheterisation and magnetic resonance imaging, which will facilitate the transfer of knowledge to patients. The development of a new therapy for patients with PH would have a great clinical impact. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Pulmonary hypertension (PH) includes a number of diseases characterised by increased pulmonary arterial pressure and pulmonary vascular resistance (RVP) and progressive deterioration of right ventricle function. Overall its prevalence is high and is associated with poor prognosis. We currently have few therapeutic alternatives, mainly in PH secondary to left heart disease (the most common one). Stimulation of ß3 adrenergic receptors produces arterial vasodilation in in vitro studies and reduction of ventricular remodeling in murine models of left ventricular overload. In pilot experiments, we have observed that the administration of ß3 agonists causes a reduction in RVP in chronic HP models in large animal, something never reported. Our hypothesis is that ß3 stimulation is a potential therapy in PH by reducing pulmonary arterial tone and remodeling and impairment of right ventricle function. In order to evaluate the beneficial effect of this new therapy at the pulmonary and cardiac level and to investigate the mechanism(s) of action, we present a translational project that includes in vitro studies on human cell lines and pulmonary arteries and HP models in rodents and pigs. In large animal experimental studies, reference diagnostic procedures shall be used in clinical practice: right cardiac catheterisation and magnetic resonance imaging, which will facilitate the transfer of knowledge to patients. The development of a new therapy for patients with PH would have a great clinical impact. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 15:49, 12 October 2021
Project Q3155217 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Stimulation of ß3 adrenergic receptors as a new therapeutic target in pulmonary hypertension. |
Project Q3155217 in Spain |
Statements
33,250.0 Euro
0 references
66,500.0 Euro
0 references
50.0 percent
0 references
1 January 2014
0 references
31 March 2017
0 references
FUNDACION CENTRO NAL DE INV. CARDIOVASCULARES CARLOS III
0 references
40°25'0.12"N, 3°42'12.89"W
0 references
28079
0 references
La hipertensión pulmonar (HP) engloba una serie de enfermedades caracterizadas por el incremento de la presión arterial pulmonar y las resistencias vasculares pulmonares (RVP) y el deterioro progresivo de la función del ventrículo derecho. Globalmente su prevalencia es alta y se asocia a mal pronóstico. Actualmente disponemos de escasas alternativas terapéuticas, fundamentalmente en la HP secundaria a cardiopatía izquierda (la más frecuente). La estimulación de los receptores ß3 adrenérgicos produce vasodilatación arterial en estudios in vitro y reducción del remodelado ventricular en modelos murinos de sobrecarga ventricular izquierda. En experimentos piloto, hemos observado que la administración de agonistas ß3 provoca una reducción de las RVP en modelos de HP crónica en animal grande, algo nunca reportado. Nuestra hipótesis es que la estimulación ß3 constituye una terapia potencial en la HP al reducir el tono y remodelado arterial pulmonar y el remodelado y deterioro de la función del ventrículo derecho. Con el objetivo de evaluar el efecto beneficioso de esta nueva terapia a nivel pulmonar y cardiaco e investigar el/los mecanismo/s de acción, presentamos un proyecto traslacional que abarca estudios in vitro sobre líneas celulares y arterias pulmonares humanas y modelos de HP en roedores y en cerdo. En los estudios experimentales en animal grande se emplearán los procedimientos diagnósticos de referencia en la práctica clínica: el cateterismo cardiaco derecho y la resonancia magnética, lo que facilitará la transferencia de los conocimientos a los pacientes. El desarrollo de una nueva terapia para los pacientes con HP tendría gran repercusión clínica. (Spanish)
0 references
Pulmonary hypertension (PH) includes a number of diseases characterised by increased pulmonary arterial pressure and pulmonary vascular resistance (RVP) and progressive deterioration of right ventricle function. Overall its prevalence is high and is associated with poor prognosis. We currently have few therapeutic alternatives, mainly in PH secondary to left heart disease (the most common one). Stimulation of ß3 adrenergic receptors produces arterial vasodilation in in vitro studies and reduction of ventricular remodeling in murine models of left ventricular overload. In pilot experiments, we have observed that the administration of ß3 agonists causes a reduction in RVP in chronic HP models in large animal, something never reported. Our hypothesis is that ß3 stimulation is a potential therapy in PH by reducing pulmonary arterial tone and remodeling and impairment of right ventricle function. In order to evaluate the beneficial effect of this new therapy at the pulmonary and cardiac level and to investigate the mechanism(s) of action, we present a translational project that includes in vitro studies on human cell lines and pulmonary arteries and HP models in rodents and pigs. In large animal experimental studies, reference diagnostic procedures shall be used in clinical practice: right cardiac catheterisation and magnetic resonance imaging, which will facilitate the transfer of knowledge to patients. The development of a new therapy for patients with PH would have a great clinical impact. (English)
12 October 2021
0 references
Madrid
0 references
Identifiers
PI13_02339
0 references